Search company, investor...

Founded Year

2009

Stage

PIPE - III | IPO

Total Raised

$75.28M

Market Cap

0.40B

Stock Price

13.73

About Nyxoah

Nyxoah (NASDAQ: NYXH) operates as a medical technology company. The company focuses on developing and commercializing a neurostimulation-based therapy for the treatment of obstructive sleep apnea (OSA). Its solution Genio system is a hypoglossal neurostimulation therapy for OSA. Nyxoah was founded in 2009 and is based in Mont-Saint-Guibert, Belgium.

Headquarters Location

Rue Edouard Belin 12

Mont Saint Guibert, 1435,

Belgium

+32 10 45 90 75

Loading...

Loading...

Expert Collections containing Nyxoah

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nyxoah is included in 1 Expert Collection, including Digital Health.

D

Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Nyxoah Patents

Nyxoah has filed 72 patents.

The 3 most popular patent topics include:

  • implants (medicine)
  • neurophysiology
  • neurotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/28/2020

1/2/2024

Sleep disorders, Neurophysiology, Fluid dynamics, Neurological disorders, Rare diseases

Grant

Application Date

7/28/2020

Grant Date

1/2/2024

Title

Related Topics

Sleep disorders, Neurophysiology, Fluid dynamics, Neurological disorders, Rare diseases

Status

Grant

Latest Nyxoah News

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Feb 15, 2024

February 15, 2024 at 04:31 pm EST Share Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah’s Q4 2023 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval. For more information, please visit http://www.nyxoah.com/. Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States. Contacts:

Nyxoah Frequently Asked Questions (FAQ)

  • When was Nyxoah founded?

    Nyxoah was founded in 2009.

  • Where is Nyxoah's headquarters?

    Nyxoah's headquarters is located at Rue Edouard Belin 12, Mont Saint Guibert.

  • What is Nyxoah's latest funding round?

    Nyxoah's latest funding round is PIPE - III.

  • How much did Nyxoah raise?

    Nyxoah raised a total of $75.28M.

  • Who are the investors of Nyxoah?

    Investors of Nyxoah include Cochlear, Otium Capital, ResMed, Uwu Wascher, Jurgen Hambrecht and 7 more.

  • Who are Nyxoah's competitors?

    Competitors of Nyxoah include ALung Technologies and 2 more.

Loading...

Compare Nyxoah to Competitors

B
Beta-O2 Technologies

Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.

P
Portaero

Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).

M
Monterey Devices

Monterey Devices specializes in the manufacturing of medical diagnostic equipment within the healthcare sector. The company offers a range of products including laryngoscopes, dermatoscopes, ENT diagnostics, and fiber optic cables, designed to support healthcare professionals in patient diagnosis and care. These products are engineered for durability and quality to meet the needs of medical practitioners. It is based in Soquel, California.

exciteOSA Logo
exciteOSA

ExciteOSA is a company that focuses on providing solutions for sleep apnea, operating within the healthcare sector. The company offers a noninvasive device that serves as a daytime therapy for mild obstructive sleep apnea, aiming to restore natural nighttime breathing. The device is designed to treat the root cause of sleep apnea, not just the symptoms, and is used for 20 minutes a day. It is based in Needham, Massachusetts.

L
LinguaFlex

Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.

R
Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.